Scarica l'app Stockscreener
0.5498
19.00%
0.0878
Pre-mercato:
.56
0.0102
+1.86%
Precedente Chiudi:
$0.462
Aprire:
$0.4866
Volume 24 ore:
181.30K
Relative Volume:
0.63
Capitalizzazione di mercato:
$1.83M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+25.50%
1M Prestazione:
-9.17%
6M Prestazione:
-92.43%
1 anno Prestazione:
-99.13%
Intervallo 1D:
$0.4849
$0.5499
Intervallo di 1 settimana:
$0.38
$0.5499
Portata 52W:
$0.3666
$108.00
Psyence Biomedical Ltd Stock (PBM) Company Profile
Nome
Psyence Biomedical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PBM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
0.5498 | 1.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Psyence Biomedical Ltd Borsa (PBM) Ultime notizie
Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks
Psyence BioMed gets Nasdaq notice for non-compliance - MSN
Psyence Group consolidates its shares - Crain's Chicago Business
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile
Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile
Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan
Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia
Psyence Biomedical reports corporate update - Investing.com
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView
Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks
Psyence's Game-Changing Phase IIb Trial Takes On Cancer Mental Health Crisis - Stock Titan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times
Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World
Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia
Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile
Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times
Psyence Biomedical files to sell 13.81M common shares for holders - MSN
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire
Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan
Psyence Biomedical Ltd (PBM) Stock: A Value Analysis - The News Heater
Ratio Analysis: Unpacking Psyence Biomedical Ltd (PBM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Psyence Biomedical Adjusts Financials for Reverse Stock Split - TipRanks
Short Interest in Psyence Biomedical Ltd. (NASDAQ:PBMWW) Decreases By 41.0% - Defense World
Psyence enters into $25M common stock purchase agreement with White Lion Capital - MSN
Psyence Biomedical Issues Pre-Funded Share Purchase Warrant - TipRanks
Psyence Biomed Announces Closing of $2.0 Million Private Placement - The Manila Times
Psyence Biomed (PBM) Raises $2M in Private Placement with Warrant Coverage, Led by H.C. Wainwright - StockTitan
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance
Psyence Biomed announces $2 million private placement By Investing.com - Investing.com Nigeria
Psyence Biomedical Ltd Azioni (PBM) Dati Finanziari
Non sono disponibili dati finanziari per Psyence Biomedical Ltd (PBM). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):